The short version of Aliquot fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-25 and is reviewed periodically as new material appears.
Reconstitution is the process of dissolving a lyophilized peptide powder in a suitable liquid to produce a solution for laboratory or clinical use. The dry powder is typically a porous cake or fluffy solid formed by freeze-drying an aqueous or mixed-solvent preparation. Adding solvent restores the peptide to a dissolved state, but the result is not necessarily identical to the original pre-lyophilization solution. Factors such as pH, ionic strength, temperature, and the peptide's sequence influence how completely and quickly dissolution occurs. The term is distinct from dilution, which lowers concentration without changing the physical state of an already dissolved material.
Solvent selection depends on the peptide's charge, hydrophobicity, and intended application. Many lyophilized peptides dissolve readily in water, while others require a small amount of a miscible organic solvent, a dilute acid, or a dilute base before aqueous dilution. A buffer may be used when a stable pH range is known, but adding buffer salts can also promote aggregation or precipitation. Dissolution should be observed rather than assumed, because a clear solution does not prove that the peptide is monomeric or fully active. The order of solvent addition and the final volume matter for achieving the intended concentration.
Concentration calculations depend on the amount of peptide present in the vial and the volume of solvent added. Lyophilized preparations often contain counterions, salts, or residual water, so the labeled mass may not equal the mass of the peptide itself. This difference can produce a calculated concentration that is higher than the true peptide concentration. Analytical determination of peptide content, rather than reliance on the vial label alone, reduces this source of error. Uncertainty in volume measurement also contributes, especially when small liquid volumes are handled.
Quality records typically include a certificate of analysis, batch number, molecular weight, purity result, and recommended storage conditions. After reconstitution, a laboratory log may record solvent, final volume, date, and storage location. Such documentation supports reproducibility and allows later investigation if a preparation behaves unexpectedly. Stability studies often examine purity and concentration over time under defined temperatures, but results are not universally transferable between peptides or formulations. Open questions remain about how best to predict aggregation for specific sequences and how much analytical testing is sufficient for routine laboratory work.
After a peptide is reconstituted, analytical checks can confirm identity, concentration, and purity. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry provides a mass value that supports sequence identity, while ultraviolet absorbance at 214 or 280 nanometers is often used for concentration estimation when the extinction coefficient is known. These methods answer different questions and are complementary. A single measurement rarely establishes full quality, because the same sample can appear acceptable by one method and fail another.
| Property | Value | Notes |
|---|---|---|
| Physical state before reconstitution | Lyophilized powder or cake | Appearance varies from fluffy to compact; not a solution. |
| Common solvent | Sterile or ultrapure water | Many peptides dissolve, but solubility is sequence-dependent. |
| Alternative solvent | Dilute acetic acid or acetonitrile/water | Used for hydrophobic or basic peptides; compatibility varies. |
| Typical storage after reconstitution | 2–8 °C short term; −20 °C or below for aliquots | Stability is peptide-specific; avoid repeated freeze-thaw. |
| Common analytical method | Reverse-phase HPLC | Assesses purity and concentration; mass spectrometry confirms identity. |
Peptide reconstitution is the process of dissolving a dried peptide preparation in a liquid solvent to form a solution. Many peptides are supplied as lyophilized powders because removing water improves stability during shipping and storage. The dried material may appear as a cake, flake, or loose powder depending on the manufacturing and drying method. Reconstitution restores the peptide to a liquid state so that it can be further diluted, analyzed, or handled in laboratory workflows. The term is distinct from dilution, which lowers concentration after a solution already exists.
The choice of solvent depends on the peptide's sequence, charge, and solubility profile. Water is common for hydrophilic peptides, while aqueous mixtures containing acetonitrile, methanol, or a small amount of acid may be needed for hydrophobic or basic sequences. Adding the liquid to the powder, rather than the reverse, can reduce clumping and improve wetting. Gentle mixing or brief vortexing may help, but vigorous agitation can create foam and shear sensitive structures. Complete dissolution is judged by a clear solution with no visible particles.
Buffer components and ionic strength affect how a peptide dissolves and remains in solution. Some sequences require a defined pH range to avoid precipitation or aggregation, while others tolerate pure water. The optimal conditions are often determined empirically because solubility cannot be predicted reliably from sequence alone. Even when a peptide dissolves, the resulting solution may contain aggregates that are not visible to the eye. Analytical methods such as reversed-phase high-performance liquid chromatography and mass spectrometry are used to confirm identity and purity after reconstitution.
After a peptide solution is prepared, its handling conditions influence how long it remains suitable for use. Solutions are typically separated into small portions to avoid repeated freeze-thaw cycles, which can promote aggregation or precipitation. Containers are chosen to minimize adsorption, especially for peptides that are hydrophobic or present at low concentration. Some laboratories use low-binding plastic tubes or add a carrier protein, although carrier addition can interfere with later analysis. Records usually note the solvent, date, and storage temperature for traceability.
Storage stability of a reconstituted peptide depends on concentration, pH, buffer composition, and the presence of oxygen or microbial contaminants. Short-term storage is often at refrigerated temperatures, while longer-term storage may use freezing at -20 °C or -80 °C. Repeated warming and cooling can cause losses through adsorption or aggregation, so aliquots are preferred. Light-sensitive peptides require protection from ambient light. Sterile filtration may be used when microbial control is needed, but filters can adsorb peptides and reduce recovery.
Quality control after reconstitution usually includes visual inspection and instrumental analysis. A clear, particle-free solution is generally expected, but color and clarity can vary with sequence and buffer. Chromatographic separation can detect degradation products, while mass confirmation verifies molecular identity. pH measurement and osmolality checks may be relevant for certain applications. Documentation of lot number, solvent, and storage history supports reproducibility and helps distinguish preparation artifacts from sample degradation. Temperature logs and freeze-thaw counts add further context when results are reviewed.
The choice of solvent is guided by peptide properties and the intended downstream use. Water alone can dissolve many hydrophilic peptides, while hydrophobic sequences may require a small amount of an organic solvent or a buffered solution. Some peptides carry net charges that affect solubility across pH values. The pH of the final solution can influence stability and aggregation. In research settings, the solvent is selected to match the assay or analytical method rather than for any therapeutic purpose.
During reconstitution, liquid is directed toward the wall of the vial rather than forcefully onto the powder. Gentle swirling or inversion mixes the contents without creating excessive foam or shear. Foaming can denature some peptides and can make volume measurement difficult. Complete dissolution is often confirmed by visual inspection against a light source. Particles, cloudiness, or undissolved material may indicate incomplete mixing, aggregation, or a solubility limitation that requires further investigation.
After a dried peptide is dissolved, the resulting solution is treated as a distinct material with its own stability profile. Temperature, pH, ionic strength, and peptide concentration all influence how long the solution remains suitable for its intended laboratory use. Some sequences are prone to oxidation, deamidation, or aggregation. Because these processes vary widely, no single storage condition applies to every peptide. Buffer composition and light exposure can also shift degradation rates.
Aseptic technique matters when the solution will contact cells or biological reagents. Working in a clean environment, using sterile liquids and containers, and minimizing open-vial time reduce the chance of microbial contamination. Filtration through a sterile filter can remove particles and microorganisms, but some filters adsorb peptides and some peptides are retained by certain membrane materials. Compatibility between the peptide, solvent, and filter should be checked when recovery is critical.
Quality verification after reconstitution may include visual inspection, pH measurement, and chromatographic analysis. Reverse-phase high-performance liquid chromatography can reveal degradation peaks, while mass spectrometry can confirm molecular identity. Concentration may be estimated from the weighed peptide mass or determined by amino acid analysis, UV absorbance, or quantitative chromatography. Documentation of solvent, volume, date, and storage conditions supports traceability and reproducibility. Records also help identify when a solution was prepared and whether it has exceeded an established in-house shelf life.
British brothers Stewart and Louis Ahearne are sentenced to three and a half years in prison by a court in Switzerland for their part in a 2019 robbery of Ming dynasty art from a museum in Geneva. The Met Office issues a warning for what is expected to be the coldest January night since 2010. Temperatures fall to −14 °C in parts of Scotland, while the following night (17 January) is the coldest of the winter for many places. Giving evidence to the inquiry into the Post Office scandal, Paul Patterson, the chief executive of Fujitsu Europe, says the company has a "moral obligation" to contribute to compensation for sub-postmasters wrongly prosecuted as a result of its faulty IT software, and apologises for the impact the scandal had on those affected by it. 17 January Data from the Office for National Statistics shows a slight increase in inflation for December 2023, with a rise to 4% compared to 3.9% in November. Broadcaster and football executive Eniola Aluko threatens to take legal action after receiving online abuse from footballer Joey Barton. Buckingham Palace confirms that King Charles III is to undergo surgery for an enlarged prostate, while Catherine, Princess of Wales is in hospital for abdominal surgery, keeping them away from public engagements for a while. The current session of the 7th Northern Ireland Assembly is suspended following the failure of Democratic Unionist Party to support nominations to elect Mike Nesbitt (UUP) or Patsy McGlone (SDLP) to the role of Speaker of the Northern Ireland Assembly.
==== Lithium levels ==== According to Stahl's Prescriber's Guide, target concentrations for acute mania should be 1.0–1.5 mEq/L. 0.6–1.0 mEq/L for depression, and 0.7–1.0 mEq/L for long-term maintenance of bipolar disorder. In the elderly, lower doses and lower lithium levels (<0.6 mEq/L) are often adequate and advisable. The Maudsley and Ghaemi prescriber's guides recommend a slightly lower lithium level of 0.8–1.0 mmol/L for acute mania. For the maintenance treatment of bipolar disorder, the International Society for Bipolar Disorders (ISBD) and International Study Group on Lithium (ISGL) guidelines recommend lithium levels of 0.6–0.8 mmol/L. In the case of good response but poor tolerance, the guidelines recommend a level of 0.4–0.6 mmol/L. In the case of insufficient response but good tolerance, the guidelines recommend a level of 0.8–1.0 mmol/L. For the maintenance treatment of the elderly, the ISBD and ISGL guidelines recommend a more conservative approach of levels of 0.4–0.6 mmol/L, with the option to go up to 0.7 or 0.8 mmol/L at ages 65–79, and up to a maximum of 0.7 mmol/L over age 80. As a result of lithium's narrow therapeutic index, toxic effects can occur at serum concentrations close to therapeutic levels, necessitating close monitoring during treatment. Initially, levels are measured every 1–2 weeks until the desired serum concentration is achieved, then every 2–3 months for the first 6 months. Once stable, levels are measured every 6–12 months. Levels of 1.2–1.5 mmol/L are considered borderline toxic. Levels above 1.5 mmol/L are considered toxic.
Business Secretary Kemi Badenoch tells the House of Commons that allegations by Henry Staunton, the former chair of the Post Office, that he was told to delay compensation payments for sub-postmasters are "completely false". The UK government announces plans for new measures on holiday homes in England to stop local people being priced out of being able to live in their community. Ofcom launches an impartiality investigation into GB News's Q&A session with prime minister Rishi Sunak. The UK government announces that a scheme allowing Ukrainian nationals to join relatives in the UK has closed to new applicants. Birmingham City Council announces plans to raise council tax by 21% over the next two years as part of £300m in budget cuts. 20 February – BBC News reports that the Cameron government were aware that the Post Office had ended a 2016 investigation that could have helped several sub-postmasters wrongly convicted as a result of the Horizon IT scandal. Labour calls for an immediate humanitarian ceasefire in Gaza, the first time it has called for a ceasefire since the Israel–Hamas conflict began. In a statement on the Israel–Hamas conflict, the Prince of Wales calls for an "end to the fighting as soon as possible". David Neal is dismissed from the post of Independent Chief Inspector of Borders and Immigration after he was quoted in articles criticising the immigration system in both The Times and the Daily Mail.
Carbon-14, C-14, 14C or radiocarbon, is a radioactive isotope of carbon with an atomic nucleus containing 6 protons and 8 neutrons. Carbon-14 was discovered on February 27, 1940, by Martin Kamen and Sam Ruben at the University of California Radiation Laboratory in Berkeley, California. Its existence had been suggested by Franz Kurie in 1934. Its presence in organic matter is the basis of the radiocarbon dating method pioneered by Willard Libby and colleagues (1949) to date archaeological, geological and hydrogeological samples. There are three naturally occurring isotopes of carbon on Earth: carbon-12 (12C), which makes up 99% of all carbon on Earth; carbon-13 (13C), which makes up 1%; and carbon-14 (14C), which occurs in trace amounts, making up about 1.2 atoms per 1012 atoms of carbon in the atmosphere. 12C and 13C are both stable; 14C is unstable, with half-life 5700±30 years, decaying into nitrogen-14 (14N) through beta decay. Pure carbon-14 would have a molar activity of 62.4 mCi/mmol (2.31 GBq/mmol), or specific activity of 164.9 GBq/g. The primary natural source of carbon-14 on Earth is cosmic ray action on nitrogen in the atmosphere, and it is therefore a cosmogenic nuclide. Open-air nuclear testing between 1955 and 1980 contributed to this pool, however. The different isotopes of carbon do not differ appreciably in their chemical properties.
Sources: en.wikipedia.org
The ligated mRNA-DNA-puromycin library is translated in Red Nova Lysate (Novagen) or E. coli S30 Extract System (Promega), resulting in peptides covalently linked in cis to the encoding mRNA. The in vitro translation can also be done in a PURE (protein synthesis using recombinant elements) system. PURE system is an E. coli cell-free translation system in which only essential translation components are present. Some components, such as amino acids and aminoacyl-tRNA synthases (AARSs) can be omitted from the system. Instead, chemically acylated tRNA can be added into the PURE system. It has been shown that some unnatural amino acids, such as N-methyl-amino acid accylated tRNA can be incorporated into peptides or mRNA-peptide fusions in a PURE system. After translation, the single-stranded mRNA portions of the fusions will be converted to heteroduplex of RNA/DNA by reverse transcriptase to eliminate any unwanted RNA secondary structures, and render the nucleic acid portion of the fusion more stable. This step is a standard reverse transcription reaction. For instance, it can be done by using Superscript II (GIBCO-BRL) following the manufacturer's protocol.
Solid-phase assays (sometimes called the "antigen capture" method) use reagent antigens or antibodies affixed to a surface (usually a microplate). Microplate wells coated with anti-A, -B and -D reagents are used for forward grouping. The test sample is added and the microplate is centrifuged; in a positive reaction, the red blood cells adhere to the surface of the well. Some automated analyzers use solid phase assays for blood typing.
The temporarily high level of 135Xe with its high neutron absorption cross-section makes it difficult to restart the reactor for several hours. The neutron-absorbing 135Xe acts like a control rod, reducing reactivity. The inability of a reactor to be started due to the effects of 135Xe is sometimes referred to as xenon-precluded start-up, and the reactor is said to be "poisoned out". The period of time that the reactor is unable to overcome the effects of 135Xe is called the "xenon dead time". If sufficient reactivity control authority is available, the reactor can be restarted, but the xenon burn-out transient must be carefully managed. As the control rods are extracted and criticality is reached, neutron flux increases many orders of magnitude and the 135Xe begins to absorb neutrons and be transmuted to 136Xe. The reactor burns off the nuclear poison. As this happens, the reactivity and neutron flux increases, and the control rods must be gradually reinserted to counter the loss of neutron absorption by the 135Xe. Otherwise, the reactor neutron flux will continue to increase, burning off even more xenon poison, on a path to runaway criticality. The time constant for this burn-off transient depends on the reactor design, power level history of the reactor for the past several days, and the new power setting. For a typical step up from 50% power to 100% power, 135Xe concentration falls for about 3 hours.
Sources: en.wikipedia.org
According to Wayman, these two are: (1) the general principle of dependent origination itself, its nidanas and their relationships and (2) how it deals with the particular process of the rebirth of sentient beings.
=== Pregnancy and breastfeeding === Clonidine is classified by the Australian Therapeutic Goods Administration as pregnancy category B3, which means that it has shown some detrimental effects on fetal development in animal studies, although the relevance of this to human beings is unknown. Clonidine appears in high concentration in breast milk; a nursing infant's serum clonidine concentration is approximately 2/3 of the mother's. Caution is warranted in women who are pregnant, planning to become pregnant, or are breastfeeding.
The patient is immunocompromised (for example, in AIDS or after chemotherapy); The infectious agent is of an uncommon nature (e.g. tropical diseases); The disease has not responded to first line antibiotics; The disease might be dangerous to other patients, and the patient might have to be isolated
Sources: en.wikipedia.org
It means adding liquid to a lyophilized peptide powder so it dissolves into solution. The dry powder is not a finished liquid product, and the resulting concentration depends on the volume added. Complete dissolution should be visually confirmed before use.
Some peptides have hydrophobic regions or strong charge interactions that make water a poor solvent alone. A small amount of organic solvent, acid, or base may be needed before aqueous dilution. The appropriate approach depends on sequence and should be based on documented compatibility.
No. Solutions can degrade through hydrolysis, oxidation, aggregation, and microbial growth, and stability varies widely by peptide. Storage at reduced temperature and avoidance of repeated freeze-thaw cycles are common laboratory practices. Specific shelf lives are determined by stability testing, not by a general rule.
Ultraviolet absorbance is common when the peptide's extinction coefficient is known. Reverse-phase HPLC with calibration standards can also estimate concentration. Amino acid analysis or quantitative mass spectrometry may be used when higher accuracy is needed.